Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Subcutaneous Injection for Optimal Results What is IGF-1 LR3
A similar pattern was observed in the SURMOUNT-4 trial for tirzepatide: after participants lost an average of 20.9% of their body weight during a 36-week lead-in phase, those who stopped treatment regained about 14%, while those who continued taking tirzepatide lost an additional 5.5% over the next year
This is not typically recommended, as clinical trials used once-weekly dosing
Liu S, Rezende R, Moreira T, et al
US$ 25.19
US$ 29.46
US$ 22.85
US$ 26.94
US$ 29.93
US$ 20.99
US$ 25.03
